SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023

Juan Manuel Carreño; Abram L Wagner; Brian Monahan; Gagandeep Singh; Daniel Floda; Ana S Gonzalez-Reiche; Johnstone Tcheou; Ariel Raskin; Dominika Bielak; Sara Morris; Miriam Fried; Temima Yellin; Leeba Sullivan; PARIS study group; Emilia Mia Sordillo; Aubree Gordon; Harm van Bakel; Viviana Simon; Florian Krammer

doi:10.1038/s41467-024-50052-2

SARS-CoV-2 serosurvey across multiple waves of the COVID-19 pandemic in New York City between 2020-2023

Nat Commun. 2024 Jul 11;15(1):5847. doi: 10.1038/s41467-024-50052-2.

Authors

Juan Manuel Carreño^#^{1

2}, Abram L Wagner^#³, Brian Monahan^{1

2}, Gagandeep Singh^{1

2}, Daniel Floda⁴, Ana S Gonzalez-Reiche⁴, Johnstone Tcheou^{1

2}, Ariel Raskin^{1

2}, Dominika Bielak^{1

2}, Sara Morris^{1

2}, Miriam Fried^{1

2}, Temima Yellin^{1

2}, Leeba Sullivan^{1

2}; PARIS study group; Emilia Mia Sordillo⁵, Aubree Gordon⁶, Harm van Bakel^{7

8

9

10}, Viviana Simon^{11

12

13

14

15}, Florian Krammer^{16

17

18

19}

Collaborators

PARIS study group:
Fatima Amanat, Guha Asthagiri Arunkumar, Christina Capuano, Jordan Ehrenhaus, Shelcie Fabre, Matthew M Hernandez, Kaijun Jiang, Brian Lerman, Meagan McMahon, Daniel Stadlbauer, Jessica Tan, Catherine Teo, Kathryn Twyman

Affiliations

¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
³ Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109, USA.
⁴ Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA.
⁵ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
⁶ Department of Epidemiology, School of Public Health, University of Michigan, 1415 Washington Heights, Ann Arbor, MI, 48109, USA. [email protected].
⁷ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
⁸ Department of Genetics and Genomic Sciences, ISMMS, New York, NY, USA. [email protected].
⁹ Icahn Genomics Institute, ISMMS, New York, NY, USA. [email protected].
¹⁰ Department of Artificial Intelligence And Human Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹¹ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹² Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹³ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁴ Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁵ The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁶ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁷ Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁸ Department of Pathology, Molecular and Cell Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. [email protected].
¹⁹ Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria. [email protected].

^# Contributed equally.

Abstract

Sero-monitoring provides context to the epidemiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and changes in population immunity following vaccine introduction. Here, we describe results of a cross-sectional hospital-based study of anti-spike seroprevalence in New York City (NYC) from February 2020 to July 2022, and a follow-up period from August 2023 to October 2023. Samples from 55,092 individuals, spanning five epidemiological waves were analyzed. Prevalence ratios (PR) were obtained using Poisson regression. Anti-spike antibody levels increased gradually over the first two waves, with a sharp increase during the 3rd wave coinciding with SARS-CoV-2 vaccination in NYC resulting in seroprevalence levels >90% by July 2022. Our data provide insights into the dynamic changes in immunity occurring in a large and diverse metropolitan community faced with a new viral pathogen and reflects the patterns of antibody responses as the pandemic transitions into an endemic stage.

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral* / blood
Antibodies, Viral* / immunology
COVID-19 Vaccines / immunology
COVID-19* / epidemiology
COVID-19* / immunology
Child
Child, Preschool
Cross-Sectional Studies
Female
Humans
Infant
Male
Middle Aged
New York City / epidemiology
Pandemics
SARS-CoV-2* / immunology
SARS-CoV-2* / isolation & purification
Seroepidemiologic Studies
Spike Glycoprotein, Coronavirus* / immunology
Young Adult

Substances

Antibodies, Viral
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2
COVID-19 Vaccines

Abstract

MeSH terms

Substances

Grants and funding